Do analysts prefer MOR or GYRE?

Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 146.02%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MOR or GYRE more profitable?

Gyre Therapeutics has a net margin of -15.47% compared to MorphoSys' net margin of -226.79%. Gyre Therapeutics' return on equity of -6.57% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Gyre Therapeutics -15.47% -6.57% -5.35%

Does the media favor GYRE or SUPN?

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Supernus Pharmaceuticals and 6 mentions for Gyre Therapeutics. Supernus Pharmaceuticals' average media sentiment score of 1.10 beat Gyre Therapeutics' score of 0.99 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GYRE or RGC?

Gyre Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 146.02%. Given Gyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, GYRE or RGC?

Gyre Therapeutics has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gyre Therapeutics $116.59M 6.61 $5.03M -$0.21 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media prefer GYRE or RGC?

In the previous week, Gyre Therapeutics had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Gyre Therapeutics and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.77 beat Gyre Therapeutics' score of 0.99 indicating that Regencell Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer GYRE or TRVI?

In the previous week, Gyre Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Gyre Therapeutics and 5 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.01 beat Gyre Therapeutics' score of 0.99 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gyre Therapeutics (GYRE) Competitors

$6.91 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

GYRE vs. MOR, SUPN, RGC, ATAI, and TRVI

Should you buy Gyre Therapeutics stock or one of its competitors? Gyre Therapeutics's main competitors and comparable companies include MorphoSys (MOR), Supernus Pharmaceuticals (SUPN), Regencell Bioscience (RGC), Atai Beckley (ATAI), and Trevi Therapeutics (TRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Gyre Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Gyre Therapeutics has a net margin of -15.47% compared to MorphoSys' net margin of -226.79%. Gyre Therapeutics' return on equity of -6.57% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Gyre Therapeutics has lower revenue, but higher earnings than MorphoSys. Gyre Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Gyre Therapeutics	$116.59M	6.61	$5.03M	-$0.21	N/A

MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 146.02%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Gyre Therapeutics had 6 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Gyre Therapeutics and 0 mentions for MorphoSys. Gyre Therapeutics' average media sentiment score of 0.99 beat MorphoSys' score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Gyre Therapeutics	Positive

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Gyre Therapeutics beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Supernus Pharmaceuticals?

Gyre Therapeutics (NASDAQ:GYRE) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

24.0% of Gyre Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Gyre Therapeutics has higher earnings, but lower revenue than Supernus Pharmaceuticals. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.61	$5.03M	-$0.21	N/A
Supernus Pharmaceuticals	$718.95M	3.71	-$38.55M	-$1.92	N/A

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Supernus Pharmaceuticals and 6 mentions for Gyre Therapeutics. Supernus Pharmaceuticals' average media sentiment score of 1.10 beat Gyre Therapeutics' score of 0.99 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gyre Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Gyre Therapeutics' net margin of -15.47%. Supernus Pharmaceuticals' return on equity of 11.13% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Gyre Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 146.02%. Supernus Pharmaceuticals has a consensus price target of $62.83, indicating a potential upside of 37.04%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Supernus Pharmaceuticals beats Gyre Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Gyre Therapeutics compare to Regencell Bioscience?

Gyre Therapeutics (NASDAQ:GYRE) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Gyre Therapeutics had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Gyre Therapeutics and 1 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.77 beat Gyre Therapeutics' score of 0.99 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Gyre Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Regencell Bioscience has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Regencell Bioscience's return on equity of 0.00% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Regencell Bioscience	N/A	N/A	N/A

Gyre Therapeutics has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.61	$5.03M	-$0.21	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Gyre Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 146.02%. Given Gyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Gyre Therapeutics beats Regencell Bioscience on 9 of the 13 factors compared between the two stocks.

How does Gyre Therapeutics compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Gyre Therapeutics has a net margin of -15.47% compared to Atai Beckley's net margin of -14,938.36%. Gyre Therapeutics' return on equity of -6.57% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Atai Beckley and Atai Beckley both had 6 articles in the media. Gyre Therapeutics' average media sentiment score of 0.99 beat Atai Beckley's score of 0.67 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atai Beckley	Positive
Gyre Therapeutics	Positive

Gyre Therapeutics has higher revenue and earnings than Atai Beckley. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	669.18	-$660.05M	-$2.18	N/A
Gyre Therapeutics	$116.59M	6.61	$5.03M	-$0.21	N/A

Atai Beckley presently has a consensus price target of $10.56, indicating a potential upside of 43.04%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 146.02%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Gyre Therapeutics beats Atai Beckley on 10 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Trevi Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Gyre Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Gyre Therapeutics and 5 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.01 beat Gyre Therapeutics' score of 0.99 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gyre Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 146.02%. Trevi Therapeutics has a consensus target price of $27.08, indicating a potential upside of 50.80%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Gyre Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.61	$5.03M	-$0.21	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Trevi Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Gyre Therapeutics' return on equity of -6.57% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Summary

Gyre Therapeutics beats Trevi Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Gyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GYRE vs. The Competition

Export

Metric	Gyre Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$770.53M	$12.49B	$7.32B	$12.82B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	-32.90	789.79	272.91	24.33
Price / Sales	6.61	795.68	639.67	97.25
Price / Cash	31.10	15.47	29.03	36.90
Price / Book	4.67	10.52	11.33	6.42
Net Income	$5.03M	$2.81B	$3.47B	$348.89M
7 Day Performance	1.47%	2.51%	2.18%	0.51%
1 Month Performance	16.33%	5.08%	7.61%	4.84%
1 Year Performance	-15.53%	7.28%	25.16%	17.04%

Gyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GYRE Gyre Therapeutics	2.6371 of 5 stars	$6.91 flat	$17.00 +146.0%	-15.5%	$770.53M	$116.59M	N/A	40
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
SUPN Supernus Pharmaceuticals	4.2191 of 5 stars	$49.03 +1.6%	$62.83 +28.2%	+2.2%	$2.81B	$718.95M	N/A	580	Positive News Gap Up
RGC Regencell Bioscience	0.4632 of 5 stars	$5.46 +2.1%	N/A	-58.6%	$2.69B	N/A	N/A	10	Positive News Gap Up
ATAI Atai Beckley	3.4129 of 5 stars	$7.29 +0.7%	$10.56 +44.8%	+61.5%	$2.69B	$4.09M	N/A	80	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GYRE) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Competitors

GYRE vs. MOR, SUPN, RGC, ATAI, and TRVI

How does Gyre Therapeutics compare to MorphoSys?

Summary

How does Gyre Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Gyre Therapeutics compare to Regencell Bioscience?

Summary

How does Gyre Therapeutics compare to Atai Beckley?

Summary

How does Gyre Therapeutics compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Competitors

GYRE vs. MOR, SUPN, RGC, ATAI, and TRVI

How does Gyre Therapeutics compare to MorphoSys?

Is MOR or GYRE more profitable?

Which has stronger earnings & valuation, MOR or GYRE?

Which has more volatility & risk, MOR or GYRE?

Do analysts prefer MOR or GYRE?

Does the media favor MOR or GYRE?

Do insiders and institutionals have more ownership in MOR or GYRE?

Summary

How does Gyre Therapeutics compare to Supernus Pharmaceuticals?

Do institutionals and insiders have more ownership in GYRE or SUPN?

Which has stronger earnings and valuation, GYRE or SUPN?

Does the media favor GYRE or SUPN?

Which has more volatility and risk, GYRE or SUPN?

Is GYRE or SUPN more profitable?

Do analysts rate GYRE or SUPN?

Summary

How does Gyre Therapeutics compare to Regencell Bioscience?

Does the media prefer GYRE or RGC?

Which has more volatility and risk, GYRE or RGC?

Do institutionals & insiders hold more shares of GYRE or RGC?

Is GYRE or RGC more profitable?

Which has better valuation and earnings, GYRE or RGC?

Do analysts prefer GYRE or RGC?

Summary

How does Gyre Therapeutics compare to Atai Beckley?

Is ATAI or GYRE more profitable?

Which has more volatility & risk, ATAI or GYRE?

Do insiders and institutionals believe in ATAI or GYRE?

Does the media refer more to ATAI or GYRE?

Which has better earnings and valuation, ATAI or GYRE?

Do analysts prefer ATAI or GYRE?

Summary

How does Gyre Therapeutics compare to Trevi Therapeutics?

Do institutionals & insiders believe in GYRE or TRVI?

Does the media prefer GYRE or TRVI?

Do analysts prefer GYRE or TRVI?

Which has more volatility and risk, GYRE or TRVI?

Which has higher valuation and earnings, GYRE or TRVI?

Is GYRE or TRVI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools